NASDAQ:MGNX MacroGenics (MGNX) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free MGNX Stock Alerts $15.22 -0.33 (-2.12%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$15.16▼$15.9950-Day Range$13.31▼$21.4752-Week Range$4.29▼$21.88Volume575,792 shsAverage Volume1.38 million shsMarket Capitalization$952.16 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get MacroGenics alerts: Email Address MacroGenics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside16.7% Upside$18.00 Price TargetShort InterestBearish14.65% of Float Sold ShortDividend StrengthN/ASustainability-1.61Upright™ Environmental ScoreNews Sentiment0.53Based on 8 Articles This WeekInsider TradingSelling Shares$1.08 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.70) to ($1.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.09 out of 5 starsMedical Sector158th out of 924 stocksPharmaceutical Preparations Industry56th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingMacroGenics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMacroGenics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.65% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in MacroGenics has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for MacroGenics is -1.61. Previous Next 2.5 News and Social Media Coverage News SentimentMacroGenics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for MacroGenics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for MGNX on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,076,848.00 in company stock.Percentage Held by Insiders11.30% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MacroGenics are expected to grow in the coming year, from ($2.70) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -96.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -96.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 6.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About MacroGenics Stock (NASDAQ:MGNX)MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Read More MGNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGNX Stock News HeadlinesApril 9, 2024 | insidertrades.comJeffrey Stuart Peters Sells 51,395 Shares of MacroGenics, Inc. (NASDAQ:MGNX) StockMay 1, 2024 | theglobeandmail.comBiotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050May 2, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 29, 2024 | americanbankingnews.comMacroGenics (NASDAQ:MGNX) Research Coverage Started at B. RileyApril 28, 2024 | americanbankingnews.comMacroGenics (NASDAQ:MGNX) Shares Gap Up to $14.37April 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for MacroGenics on Strong Oncology Pipeline and Positive Phase II Trial ResultsApril 21, 2024 | finance.yahoo.comMacroGenics, Inc. (MGNX)April 19, 2024 | finance.yahoo.comWe're Hopeful That MacroGenics (NASDAQ:MGNX) Will Use Its Cash WiselyMay 2, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…April 18, 2024 | ca.finance.yahoo.comMacroGenics, Inc. (MGNX) Interactive Stock Chart - Yahoo FinanceApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for MacroGenics with Promising Vobra Duo Data and Anticipated 2024 ClarificationsApril 10, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - MGNXApril 6, 2024 | uk.investing.comMacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer CandidateApril 5, 2024 | seekingalpha.comMacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024April 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for MacroGenics on Strong Safety Profile and Anticipated Efficacy DataApril 4, 2024 | markets.businessinsider.comThe Latest Analyst Ratings For MacrogenicsApril 4, 2024 | markets.businessinsider.comSimulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market SessionApril 4, 2024 | msn.comMacroGenics gains after mid-stage data for antibody drug conjugateApril 4, 2024 | markets.businessinsider.comPositive Outlook for MacroGenics: Buy Rating Affirmed Amid Vobra-duo DevelopmentsApril 3, 2024 | globenewswire.comMacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future DisclosuresMarch 16, 2024 | finance.yahoo.comMGNX Apr 2024 10.000 putMarch 16, 2024 | finance.yahoo.comMGNX Dec 2024 17.500 putMarch 15, 2024 | ca.finance.yahoo.comMGNX Mar 2024 22.500 putMarch 14, 2024 | msn.comThe Potential of MacroGenics’ (NASDAQ:MGNX) Pipeline is Driving the StockMarch 14, 2024 | finance.yahoo.comMacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call TranscriptMarch 11, 2024 | realmoney.thestreet.comMacroGenics price target raised by $6 at JMP Securities, here's whyMarch 11, 2024 | msn.com3 Best Stocks to Buy Now, 3/11/2024, According to Top AnalystsSee More Headlines Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/02/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MGNX CUSIPN/A CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees339Year Founded2000Price Target and Rating Average Stock Price Target$18.00 High Stock Price Target$25.00 Low Stock Price Target$12.00 Potential Upside/Downside+18.2%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,060,000.00 Net Margins-15.42% Pretax Margin-15.42% Return on Equity-88.49% Return on Assets-43.12% Debt Debt-to-Equity RatioN/A Current Ratio4.48 Quick Ratio4.46 Sales & Book Value Annual Sales$58.75 million Price / Sales16.22 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book6.19Miscellaneous Outstanding Shares62,560,000Free Float55,492,000Market Cap$952.79 million OptionableOptionable Beta2.09 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Scott Koenig M.D. (Age 72)Ph.D., President, CEO & Director Comp: $1.2MMr. James Karrels (Age 57)Senior VP, CFO & Corporate Secretary Comp: $693.31kDr. Stephen L. Eck M.D. (Age 69)Ph.D., Senior VP of Clinical Development & Chief Medical Officer Comp: $766.85kMr. Eric Blasius Risser (Age 51)Chief Operating Officer Comp: $651.36kDr. Thomas M. Spitznagel Ph.D. (Age 57)Senior Vice President of Technical Operations Comp: $550.97kDr. Ezio Bonvini M.D. (Age 70)Senior VP of Research & Chief Scientific Officer Comp: $612.21kMr. Jeffrey Stuart Peters (Age 53)Senior VP, General Counsel & Corporate Compliance Officer Ms. Lynn Cilinski (Age 66)VP, Controller & Treasurer More ExecutivesKey CompetitorsCentessa PharmaceuticalsNASDAQ:CNTAABIVAX Société AnonymeNASDAQ:ABVXTyra BiosciencesNASDAQ:TYRACassava SciencesNASDAQ:SAVALiquidiaNASDAQ:LQDAView All CompetitorsInsiders & InstitutionsMirae Asset Global Investments Co. Ltd.Bought 7,723 shares on 5/1/2024Ownership: 0.091%BNP Paribas Financial MarketsSold 6,796 shares on 5/1/2024Ownership: 0.056%Allspring Global Investments Holdings LLCSold 28,133 shares on 4/30/2024Ownership: 0.020%Principal Financial Group Inc.Bought 76,727 shares on 4/29/2024Ownership: 0.551%China Universal Asset Management Co. Ltd.Bought 4,761 shares on 4/29/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions MGNX Stock Analysis - Frequently Asked Questions Should I buy or sell MacroGenics stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MGNX shares. View MGNX analyst ratings or view top-rated stocks. What is MacroGenics' stock price target for 2024? 9 brokers have issued 12 month price objectives for MacroGenics' stock. Their MGNX share price targets range from $12.00 to $25.00. On average, they anticipate the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 16.7% from the stock's current price. View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts. How have MGNX shares performed in 2024? MacroGenics' stock was trading at $9.62 at the beginning of the year. Since then, MGNX stock has increased by 60.4% and is now trading at $15.43. View the best growth stocks for 2024 here. Are investors shorting MacroGenics? MacroGenics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 8,600,000 shares, an increase of 33.3% from the March 31st total of 6,450,000 shares. Based on an average daily volume of 1,540,000 shares, the days-to-cover ratio is presently 5.6 days. Approximately 14.7% of the company's shares are short sold. View MacroGenics' Short Interest. When is MacroGenics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MGNX earnings forecast. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) released its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.49. The biopharmaceutical company earned $10.72 million during the quarter, compared to analyst estimates of $25.70 million. MacroGenics had a negative net margin of 15.42% and a negative trailing twelve-month return on equity of 88.49%. During the same period in the previous year, the business earned $0.21 earnings per share. What ETFs hold MacroGenics' stock? ETFs with the largest weight of MacroGenics (NASDAQ:MGNX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).iShares Genomics Immunology and Healthcare ETF (IDNA). What is Scott Koenig's approval rating as MacroGenics' CEO? 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC). Who are MacroGenics' major shareholders? MacroGenics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (1.58%), Pinnacle Associates Ltd. (1.03%), Principal Financial Group Inc. (0.55%), Mirae Asset Global Investments Co. Ltd. (0.09%), Los Angeles Capital Management LLC (0.09%) and BNP Paribas Financial Markets (0.06%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel. View institutional ownership trends. How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MGNX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry ResearchTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.